• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PYRAZINAMIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • PYRAZINAMIDE chembl:CHEMBL614 Approved

    Alternate Names:

    PYRAZINECARBOXAMIDE
    D-50
    PIRILENE
    NSC-14911
    PYRAFAT
    TEBRAZID
    PYRAZINAMIDE
    MK-56
    PYRAZINE-2-CARBOXAMIDE
    PZA
    2-CARBAMYLPYRAZINE
    PYRAZINOIC ACID AMIDE
    PYRAZINE CARBOXAMIDE
    PYRAZINAMIDA
    PYRIZINAMIDE
    ALDINAMIDE
    PIRAZINAMIDA
    PYRAZINEAMIDE
    PYRAZINAMID
    2-PYRAZINECARBOXAMIDE
    PIRAZINAMIDE
    PYRAZINAMIDUM
    ZINAMIDE®
    drugbank:00339
    rxcui:8987
    chembl:CHEMBL614
    pubchem.compound:1046
    chemidplus:98-96-4

    Drug Info:

    (1 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Kim SH et al., 2011, NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption., Eur J Clin Pharmacol
    Zeis, 1988, Antimycobacterial drugs and the production of reactive oxidants by polymorphonuclear leucocytes in vitro., Chemotherapy
    Kim SH et al., 2012, TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis., Liver Int
    Wang Y et al., 2017, Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population., Infect Genet Evol
  • PYRAZINAMIDE   MPO

    Interaction Score: 0.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2832129


    Sources:
    NCI

  • PYRAZINAMIDE   CYP2B6

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28389387


    Sources:
    PharmGKB

  • PYRAZINAMIDE   TNF

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22151084


    Sources:
    PharmGKB

  • PYRAZINAMIDE   CYP2C9

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300 20941486


    Sources:
    DTC PharmGKB

  • PYRAZINAMIDE   CYP2C19

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC PharmGKB

  • PYRAZINAMIDE   CYP1A2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PYRAZINAMIDE   CYP2D6

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PYRAZINAMIDE   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • NCI: PYRAZINAMIDE

    • Version: 14-September-2017

    Alternate Names:
    C29395 NCI drug code

    Drug Info:

    Publications:
    Zeis, 1988, Antimycobacterial drugs and the production of reactive oxidants by polymorphonuclear leucocytes in vitro., Chemotherapy

  • DTC: PYRAZINAMIDE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL614 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: pyrazinamide

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Kim SH et al., 2011, NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption., Eur J Clin Pharmacol
    Kim SH et al., 2012, TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis., Liver Int
    Wang Y et al., 2017, Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population., Infect Genet Evol

  • TTD: Pyrazinamide

    • Version: 2020.06.01

    Alternate Names:
    D0XF8W TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL614

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21